SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

English version Introducing SWFTCoin (SWFTC) $SWFTC: Powering SWFT Blockchain and AI Services (SWFTGPT)  SwftCoin ($SWFTC) is the native utility token driving SWFT Blockchain's AI-powered ecosystem, SWFTGPT, and the first ever AI token featured on Coinbase. SWFTGPT is also the first domain-specific LLM for crypto.  SwftCoin key features include: 50% Reduced Transaction Fees: Lower costs on all transactions. AI Service Payments: Use $SWFTC to access SWFTGPT. Tools include expert market analysis,  predictions, and intelligent trading solutions.  Membership Benefits: Unlock premium features and AI agent services within SWFTGPT. AI-Powered Swaps: Enable precise, fast cross-chain transactions and analytics. SWFT Blockchain combines AI innovation with blockchain infrastructure, simplifying crypto trading while enhancing functionality through $SWFTC.   Chinese version $SWFTC：驱动 SWFT Blockchain 和 AI 服务（SWFTGPT） SwftCoin ($SWFTC) 是 SWFT Blockchain 的原生实用代币，为其 AI 驱动的生态系统 SWFTGPT 提供支持，同时也是 Coinbase 上首个 AI 代币。SWFTGPT 也是首个专注于加密领域的特定领域大型语言模型 (LLM)。 SwftCoin 的主要功能包括： 1、50% 交易费减免：降低所有交易成本。 2、AI 服务支付：使用 $SWFTC 访问 SWFTGPT 工具，包括专家市场分析、预测以及智能交易解决方案。 3、会员权益：解锁 SWFTGPT 的高级功能和 AI 代理服务。 4、AI 驱动的闪兑：实现精准快速的跨链交易和数据分析。 SWFT Blockchain 将 AI 创新与区块链基础设施结合，通过 $SWFTC 简化加密交易，并提升其功能性。

SwftCoin

SwftCoin is experiencing increased attention, with community members pointing to its fully diluted status and potential for significant price movement. Conversations revolve around possible catalysts and the right timing for a breakout, with some drawing comparisons to other altcoins. Despite some skepticism, optimism persists, fueled by the belief that the project has underlying utility.

Intuition is the L2 for trusted data, and the world's first token-curated graph—allowing people and machines to get the information they need, when they need it, from the sources they trust. With Intuition, you can put your 'intuition' to work—transforming your thoughts, opinions, and experiences into fuel for personalized AI, recommendations, and ads that truly understand you. You fully control your digital identity and data—the most valuable resources of the digital age—enabling you to fully leverage their value while unlocking and democratizing trillions in economic potential. Bring your social graphs, preferences, and 'intuition' with you wherever you go. No more rebuilding your profile and connections from scratch on every new platform—create and curate a universal, portable identity and context that allows applications and AI across the web to understand you instantly. And as you contribute, you’re not just improving your own experience—you’re enhancing the web for everyone who follows and trusts your perspective.

Trust Community Token

Trust Community Token ($TRUST) is seeing active discussion around potential 'round 2' buying opportunities after an apparent sell-off, with some community members taking profits and moving to other tokens. Despite some negative sentiment and concerns about a potential rug pull, others remain optimistic, highlighting recent Coinbase listings and potential for significant gains during the altcoin season.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - 8% PRF PERPETUAL USD 100 - Ser A

Strategy Inc 8.00% Series A Perpetual Strike Preferred Stock

STRK is trending as investors discuss its relationship to Strategy's Bitcoin holdings and dividend payouts. Community members are weighing the benefits and risks, particularly concerning potential dilution and the connection to $MSTR's performance. Bullish sentiment seems to be driven by confidence in Strategy's overall approach to BTC accumulation.

Banco de Chile SA engages in the provision of banking services. It operates through the following segments: Retail Banking, Wholesale Banking, Treasury, and Money Markets, and Subsidiaries. The Retail Banking segment consists of consumer loans, commercial loans, checking accounts, credit cards, credit lines, and mortgage loans. The Wholesale Banking segment includes corporate clients and large companies where the product offering focuses on commercial loans, checking accounts and liquidity management services, debt instruments, foreign trade, derivative contracts, and leases. The Treasury and Money Markets segment comprises securities portfolio, derivatives positions, and currency trading. The Subsidiaries segment corresponds to companies and corporations controlled by the bank. The company was founded on October 28, 1893 and is headquartered in Santiago, Chile.

Banco de Chile - ADR

Banco de Chile

Banco de Chile is trending due to a mix of options trading activity and analyst rating updates, including some upgrades. The community is discussing potential profit margins on call and put contracts, along with target entry and exit prices. Some analysts have updated their rating on Banco de Chile.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain and as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is trending amidst discussions about potential market manipulation and future price movements, with some traders anticipating a pump while others remain skeptical. Community members are actively debating its correlation with Bitcoin and the potential impact of the upcoming Goliath Testnet. Recent developments, like exchange listings and staking updates, are also fueling conversations around the coin's future.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending amidst discussions around its recent integration with NatPay and speculation regarding future partnerships, including potential collaborations with Swift and J.P. Morgan. The community is weighing the significance of these developments, with some expressing excitement about Zebec's potential for real-world payment infrastructure and others remaining cautious. Participants are actively discussing staking opportunities and debating the impact of broader market trends, with some viewing the current price as a buying opportunity.

Pump Mind Virus is a Pure Meme with a long term vision. We are building for the future while making no promises about the present. The project aims to bring the spirit of community memes back to the Solana ecosystem. We do that with engaging content and memes. Culture through community. Viral spread by word of mouth.  And most importantly, by not using the fake hype machine that has come to dominate the meme coin landscape.

PumpMindVirus

$PMV is trending due to its active and meme-heavy community, driving excitement around its 'infected' narrative. The coin, part of the $PUMP ecosystem on $SOL, is gaining attention for its strong community and potential for growth. Community members highlight the coin's potential to reach a significant market cap, with many mentioning its organic growth.

Aventus Network

Aventus Network ($AVT) is trending amid community excitement surrounding its Polkadot integration and real-world enterprise partnerships with Vodafone and Heathrow. The recent addition of Dr. Marwan Al Zarouni as a strategic advisor to expand its reach in the UAE has sparked additional buzz. Traders are monitoring volume closely, anticipating potential catalysts like new exchange listings to drive price movement.

WorldFinancial

WorldFinancial (WLFI) is experiencing a surge in interest, with community members attributing the recent price action to speculation around potential catalysts. Discussions include the recent pardon of Zhao, the Binance founder, and anticipation surrounding the release of the WLFI app and borrowing features. Despite some skepticism and concerns about its association with the Trump family, bullish sentiment persists due to the low token circulation and potential for future developments.

Albemarle Corp. engages in the development, manufacture, and marketing of chemicals for consumer electronics, petroleum refining, utilities, packaging, construction, transportation, pharmaceuticals, crop production, food-safety, and custom chemistry services. It operates through the following segments: Energy Storage, Specialties, Ketjen, and All Other. The Energy Storage segment develops and manufactures a broad range of basic lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride. The Specialties segment focuses on optimizing a portfolio of bromine and specialized lithium solutions. The Ketjen segment consists of clean fuels technologies, fluidized catalytic cracking catalysts and additives, and performance catalyst solutions, which is primarily composed of organometallics and curatives. The All Other segment refers only to the FCS business that did not fit into any of the company’s core businesses. The company was founded in 1993 and is headquartered in Charlotte, NC.

Albemarle Corp.

Albemarle Corp

Albemarle is trending amid discussions around lithium demand, potential government support, and technical analysis pointing to a possible breakout. Community members are weighing in on entry points, price targets, and the impact of factors like Chinese production and trade tensions. Bullish sentiment is growing as some see the stock as undervalued with potential for significant upside.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Global stock market chart and trading board - stock photo

Evaxion Appoints Helen Tayton-Martin As Chief Executive

Tayton-Martin will take over as the CEO on November 24, the company said.

Equity

Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation

Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation PR Newswire VANCOUVER, BC, Oct. 17, 2025...

Evaxion A/S (EVAX) said on Thursday that it has out-licensed its vaccine candidate EVX-B3 to Merck (MRK), sending shares of the company rallying 42% in the pre-market session.Evaxion will receive a cash payment of $7.5 million in addition to future milestone payments of up to $592 million, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://evaxion.ai/investors/press-releases/?press_release_id=10586">said</a>. It will also be eligible for royalties on net sales.The cash payment will extend Evaxion’s cash runway to the first half of 2027, it said. Cash at hand will be invested in operating and developing the business, it added.The out-licensing is part of the option and license agreement between the two companies in September 2024. Merck will now be wholly responsible for the further development of the EVX-B3 vaccine, which is in preclinical development.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/EVAX">EVAX stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.EVX-B3 was discovered and developed in a collaboration between Evaxion and Merck. It aims to address a serious global medical issue for which no vaccines are currently available, Evaxion said, without naming the condition.Merck retains an option in a second vaccine candidate called EVX-B2. It is a preclinical vaccine candidate against Gonorrhea, and a decision on potential licensing is expected in the first half of 2026. Were Merck to exercise the option, Evaxion will receive a cash payment of $2.5 million and will be eligible for milestone payments of up $592 million in addition to royalties on sales.EVAX stock is down 22% this year and approximately 77% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/capricor-stock-rises-pre-market-over-fresh-hopes-of-deramiocel-approval-in-treating-genetic-disorder/chDlIyZR34h">Capricor Stock Rises Pre-Market Over Fresh Hopes of Deramiocel Approval In Treating Genetic Disorder</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Evaxion Stock Jumps A Whopping 43% Pre-Market – Here’s What Happened

The company said it will receive a cash payment of $7.5 million, in addition to future milestone payments of up to $592 million.

Evaxion Biotech A/S (NASDAQ:EVAX) Stock Rating Upgraded by LADENBURG THALM/SH SH

LADENBURG THALM/SH SH upgraded shares of Evaxion Biotech A/S (NASDAQ:EVAX - Free Report) from a neutral rating to a buy rating in a report published on Tuesday, Marketbeat.com reports. The firm...

Q4 2023 Evaxion Biotech A/S Earnings Call (Danish) Transcript

Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection

Evaxion and its collaborator tested Evaxion-designed vaccine antigens against Staphylococcus aureus in a clinically relevant animal model of surgical site infectionsThe vaccine antigens significantly...

Evaxion Biotech Announces Upcoming Annual Meeting

Evaxion Biotech A/S Adr (EVAX) has released an update. Evaxion Biotech A/S has announced its annual general meeting scheduled for April 16, 2024, e...

Evaxion Announces Business Update and Full Year 2023 Financial Results

Precision vaccine project initiated with the ambition to obtain Preclinical Proof-of-Concept by H2 2024. The novel concept entails AI-identification of a new class of cancer vaccine targets, named...

Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology  Platform

The proprietary AI-Immunology platform brings the potential for a new era in vaccine discovery, design and development using advanced AI and machine learning technologiesAI-Immunology outcompetes...

Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations

COPENHAGEN, Denmark, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ( Evaxion or the Company ), a clinical-stage TechBio company specializing in developing AI-Immunology...

Evaxion AS engages in the discovery and development of immunotherapies for cancer and infectious diseases. Its technologies include the immuno-oncology platform PIONEER, the bacterial disease platform EDEN, the viral disease platform RAVEN, and the proprietary AI platform technology ObsERV. The company was founded by Niels Iversen Møller and Andreas Holm Mattsson on August 11, 2008 and is headquartered in Hoersholm, Denmark.

Current Price	$5.13
Prev Close	$5.34
Open	$5.44
Dividend Yield	0.00%
50-Day Moving Average	$5.47
Beta	0.63
Avg. Volume	806,615.13
PE Ratio	-0.87

52-Week High	$12.15
52-Week Low	$1.20
Market Capitalization	$32.72M
EPS (Annual)	-$9.83
Price to Book	5.26
Revenue Per Employee	$72,579.04
Enterprise Value/EBITDA	N/A

EVAX
Evaxion Biotech

Feed

News

Sentiment

Fundamentals

Info

Latest EVAX News

EVAXEvaxion Biotech